ImmunoPrecise Antibodies (IPA) Competitors $2.70 +0.70 (+35.00%) Closing price 04:00 PM EasternExtended Trading$2.74 +0.04 (+1.67%) As of 04:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock IPA vs. ATXS, NBTX, FULC, IVA, TNXP, AURA, ARCT, CRVS, ABEO, and OLMAShould you be buying ImmunoPrecise Antibodies stock or one of its competitors? The main competitors of ImmunoPrecise Antibodies include Astria Therapeutics (ATXS), Nanobiotix (NBTX), Fulcrum Therapeutics (FULC), Inventiva (IVA), Tonix Pharmaceuticals (TNXP), Aura Biosciences (AURA), Arcturus Therapeutics (ARCT), Corvus Pharmaceuticals (CRVS), Abeona Therapeutics (ABEO), and Olema Pharmaceuticals (OLMA). These companies are all part of the "pharmaceutical products" industry. ImmunoPrecise Antibodies vs. Its Competitors Astria Therapeutics Nanobiotix Fulcrum Therapeutics Inventiva Tonix Pharmaceuticals Aura Biosciences Arcturus Therapeutics Corvus Pharmaceuticals Abeona Therapeutics Olema Pharmaceuticals Astria Therapeutics (NASDAQ:ATXS) and ImmunoPrecise Antibodies (NASDAQ:IPA) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, valuation, analyst recommendations, media sentiment and dividends. Does the media prefer ATXS or IPA? In the previous week, Astria Therapeutics had 32 more articles in the media than ImmunoPrecise Antibodies. MarketBeat recorded 34 mentions for Astria Therapeutics and 2 mentions for ImmunoPrecise Antibodies. Astria Therapeutics' average media sentiment score of 0.97 beat ImmunoPrecise Antibodies' score of 0.44 indicating that Astria Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Astria Therapeutics Positive ImmunoPrecise Antibodies Neutral Do analysts recommend ATXS or IPA? Astria Therapeutics currently has a consensus price target of $29.00, indicating a potential upside of 327.73%. ImmunoPrecise Antibodies has a consensus price target of $4.00, indicating a potential upside of 48.15%. Given Astria Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Astria Therapeutics is more favorable than ImmunoPrecise Antibodies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Astria Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.14ImmunoPrecise Antibodies 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has better earnings and valuation, ATXS or IPA? ImmunoPrecise Antibodies has higher revenue and earnings than Astria Therapeutics. ImmunoPrecise Antibodies is trading at a lower price-to-earnings ratio than Astria Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAstria TherapeuticsN/AN/A-$94.26M-$2.01-3.37ImmunoPrecise Antibodies$17.59M7.08-$21.69M-$0.68-3.97 Which has more risk & volatility, ATXS or IPA? Astria Therapeutics has a beta of 0.48, suggesting that its stock price is 52% less volatile than the S&P 500. Comparatively, ImmunoPrecise Antibodies has a beta of 0.49, suggesting that its stock price is 51% less volatile than the S&P 500. Do insiders and institutionals have more ownership in ATXS or IPA? 99.0% of Astria Therapeutics shares are owned by institutional investors. Comparatively, 6.7% of ImmunoPrecise Antibodies shares are owned by institutional investors. 4.5% of Astria Therapeutics shares are owned by insiders. Comparatively, 6.8% of ImmunoPrecise Antibodies shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Is ATXS or IPA more profitable? Astria Therapeutics has a net margin of 0.00% compared to ImmunoPrecise Antibodies' net margin of -122.10%. ImmunoPrecise Antibodies' return on equity of -40.62% beat Astria Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Astria TherapeuticsN/A -56.39% -36.08% ImmunoPrecise Antibodies -122.10%-40.62%-22.19% SummaryAstria Therapeutics beats ImmunoPrecise Antibodies on 9 of the 16 factors compared between the two stocks. Get ImmunoPrecise Antibodies News Delivered to You Automatically Sign up to receive the latest news and ratings for IPA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IPA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IPA vs. The Competition Export to ExcelMetricImmunoPrecise AntibodiesMEDICAL INFO SYS IndustryMedical SectorNASDAQ ExchangeMarket Cap$124.61M$2.10B$5.70B$9.79BDividend YieldN/AN/A3.77%4.10%P/E Ratio-3.9737.0330.8625.25Price / Sales7.0810.14403.9088.50Price / CashN/A51.0625.2228.45Price / Book7.3010.889.516.00Net Income-$21.69M-$63.67M$3.26B$265.34M7 Day Performance42.11%6.11%4.49%2.81%1 Month Performance56.07%2.88%5.18%1.50%1 Year Performance164.71%29.43%31.98%25.46% ImmunoPrecise Antibodies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IPAImmunoPrecise Antibodies2.2745 of 5 stars$2.70+35.0%$4.00+48.1%+96.1%$124.61M$17.59M-3.9780Short Interest ↑High Trading VolumeATXSAstria Therapeutics2.6927 of 5 stars$6.68+6.4%$29.00+334.1%-38.7%$354.41MN/A-3.5730News CoverageEarnings ReportAnalyst RevisionNBTXNanobiotix0.8208 of 5 stars$7.18-2.8%$8.00+11.5%+59.8%$353.82M$39.18M0.00100News CoverageShort Interest ↑Gap UpFULCFulcrum Therapeutics1.3605 of 5 stars$6.34-2.3%$7.57+19.4%-26.2%$351.05M$80M-5.20100IVAInventiva3.5953 of 5 stars$3.52-1.7%$10.40+195.5%+98.2%$342.47M$9.95M0.00100Short Interest ↓Gap DownTNXPTonix Pharmaceuticals2.6153 of 5 stars$44.97-3.3%$70.00+55.7%+15.0%$342.04M$10.09M-0.0250News CoverageEarnings ReportAnalyst RevisionGap UpTrading HaltedAURAAura Biosciences1.6563 of 5 stars$6.84+0.6%$22.00+221.6%-14.7%$341.83MN/A-3.6050News CoverageEarnings ReportAnalyst RevisionARCTArcturus Therapeutics2.8813 of 5 stars$11.39-4.4%$50.80+346.0%-3.6%$323.01M$152.31M-4.50180Earnings ReportHigh Trading VolumeCRVSCorvus Pharmaceuticals2.9019 of 5 stars$4.37+1.4%$15.00+243.2%+32.4%$321.15MN/A-4.3330ABEOAbeona Therapeutics4.5665 of 5 stars$6.28+0.3%$19.25+206.5%+42.6%$320.24M$3.50M-4.9490News CoverageEarnings ReportAnalyst ForecastOLMAOlema Pharmaceuticals2.1336 of 5 stars$4.57-1.5%$24.50+436.1%-54.9%$317.48MN/A-2.2770Earnings Report Related Companies and Tools Related Companies Astria Therapeutics Alternatives Nanobiotix Alternatives Fulcrum Therapeutics Alternatives Inventiva Alternatives Tonix Pharmaceuticals Alternatives Aura Biosciences Alternatives Arcturus Therapeutics Alternatives Corvus Pharmaceuticals Alternatives Abeona Therapeutics Alternatives Olema Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IPA) was last updated on 8/18/2025 by MarketBeat.com Staff From Our PartnersBiotech Alert: With news on MPox, RSV, and more, this tiny firm could disrupt a $3B marketA small biotech is stepping into the spotlight with a first-in-class antiviral platform—and it could be one of...Smallcaps Daily | SponsoredFormer CIA Officer Reveals How Gold Saved His Life This isn’t just another gold investing book—it’s a survival playbook written by a former CIA officer trained...Advantage Gold | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThe stealth altcoin the financial world is underestimatingThis DeFi project could soar next When altcoin season fully kicks in—which the data suggests is happening R...Crypto 101 Media | SponsoredNew law could create $3.7 trillion tsunami.During a meeting in Washington D.C., Jeff Brown discovered a bold initiative. He calls it “President Trump’...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ImmunoPrecise Antibodies Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share ImmunoPrecise Antibodies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access